ATE212847T1 - Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten - Google Patents

Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten

Info

Publication number
ATE212847T1
ATE212847T1 AT96928381T AT96928381T ATE212847T1 AT E212847 T1 ATE212847 T1 AT E212847T1 AT 96928381 T AT96928381 T AT 96928381T AT 96928381 T AT96928381 T AT 96928381T AT E212847 T1 ATE212847 T1 AT E212847T1
Authority
AT
Austria
Prior art keywords
pct
substants
antineoplastic
phenol substituted
sec
Prior art date
Application number
AT96928381T
Other languages
English (en)
Inventor
Eric Niesor
Craig Leigh Bentzen
Lan Mong Nguyen
Jean-Luc Thuillard
Hieu Trung Phan
Jean Flach
Original Assignee
Symphar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphar Sa filed Critical Symphar Sa
Application granted granted Critical
Publication of ATE212847T1 publication Critical patent/ATE212847T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/404Esters of poly(thio)phosphonic acids containing hydroxy substituents in the hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96928381T 1995-07-28 1996-07-26 Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten ATE212847T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH02213/95A CH690163A5 (fr) 1995-07-28 1995-07-28 Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
PCT/EP1996/003301 WO1997004785A1 (en) 1995-07-28 1996-07-26 Use of phenol substituted diphosphonates as antineoplastic agents

Publications (1)

Publication Number Publication Date
ATE212847T1 true ATE212847T1 (de) 2002-02-15

Family

ID=4228513

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928381T ATE212847T1 (de) 1995-07-28 1996-07-26 Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten

Country Status (14)

Country Link
US (1) US6127350A (de)
EP (1) EP0845991B1 (de)
JP (1) JPH11511127A (de)
CN (1) CN1091601C (de)
AT (1) ATE212847T1 (de)
AU (1) AU723094B2 (de)
CA (1) CA2228212A1 (de)
CH (1) CH690163A5 (de)
DE (1) DE69619117T2 (de)
DK (1) DK0845991T3 (de)
ES (1) ES2172675T3 (de)
PT (1) PT845991E (de)
WO (1) WO1997004785A1 (de)
ZA (1) ZA966364B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603637D0 (en) * 1996-02-21 1996-04-17 Smithkline Beecham Plc Process
EP0998934A4 (de) * 1997-12-25 2005-09-14 Toray Industries Heilmittel gegen intramedullare krankheiten
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
GB0019272D0 (en) * 2000-08-04 2000-09-27 Symphar Sa Pharmaceutical compounds
FR2827289B1 (fr) * 2001-07-16 2004-07-23 Univ Paris 13 Nouveau derive d'acide diphosphonique, son application en therapeutique et procede de preparation
ES2336312T3 (es) 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
JP2005511526A (ja) * 2001-10-18 2005-04-28 イレックス プロダクツ インコーポレイテッド ジホスホネート誘導体による皮膚の治療方法
EP1506208A4 (de) * 2002-05-11 2006-05-24 Ilex Products Inc 1,1- und 1,2-bisphosphonate als modulatoren von apolipoprotein e
JP2006503023A (ja) * 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法
WO2004026242A2 (en) * 2002-09-19 2004-04-01 Ilex Oncology Research, Sarl Substituted ketophosphonate inhibitors of tumor cell proliferation
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2649288C (en) 2006-04-19 2015-11-24 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (de) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP3400943B1 (de) * 2012-03-23 2020-12-02 Array Biopharma, Inc. Verbindungen zur verwendung bei der behandlung von hirnmetastasen bei einem patienten mit erbb2+ brustkrebs
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (de) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclische inhibitoren der cyclin-dependent-kinase 7 (cdk7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3209671B8 (de) 2014-10-21 2019-07-31 Council of Scientific and Industrial Research Alkyliden-phosphonat-ester als p-glycoproteininduktoren
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106986789B (zh) * 2016-01-20 2019-07-16 中国人民解放军军事医学科学院生物医学分析中心 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3525785B1 (de) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5-inhibitoren
KR102702926B1 (ko) 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
EP3706747B1 (de) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3810132A4 (de) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. Kinaseinhibitoren der taire und ihre verwendungen
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4673747A1 (de) 2023-03-02 2026-01-07 CARCIMUN BIOTECH GmbH Mittel und verfahren zur diagnose von krebs und/oder einer akuten entzündungskrankheit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675422A5 (de) * 1988-03-31 1990-09-28 Symphar Sa
JPH0377894A (ja) * 1989-08-18 1991-04-03 Toray Ind Inc メチレンジホスホン酸化合物

Also Published As

Publication number Publication date
AU723094B2 (en) 2000-08-17
CN1192148A (zh) 1998-09-02
JPH11511127A (ja) 1999-09-28
EP0845991A2 (de) 1998-06-10
ES2172675T3 (es) 2002-10-01
PT845991E (pt) 2002-07-31
DE69619117T2 (de) 2002-09-19
DE69619117D1 (de) 2002-03-21
CA2228212A1 (en) 1997-02-13
CH690163A5 (fr) 2000-05-31
HK1015686A1 (en) 1999-10-22
ZA966364B (en) 1997-02-11
WO1997004785A1 (en) 1997-02-13
AU6787496A (en) 1997-02-26
DK0845991T3 (da) 2002-05-27
CN1091601C (zh) 2002-10-02
EP0845991B1 (de) 2002-02-06
US6127350A (en) 2000-10-03

Similar Documents

Publication Publication Date Title
ATE212847T1 (de) Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten
FI924427A0 (fi) Bensylfosfonsyratyrosinkinas -inhibitorer.
PT841929E (pt) Quinolonas e sua utilizacao terapeutica
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
DE69528470D1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
AU1642795A (en) Substituted pyridylpyrazoles
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
BR9609888A (pt) Halogenobenzimidazóis
MX206851B (es) Aril o heteroarilamidas sustituidas que tienen actividad biologica similar a los retinoides.
TR199802296T2 (xx) Yeni 2,3 dis�bstit�te-4 (3H)-kinazolinonlar
FI934223A0 (fi) Heterocykliscykliska aminderivat
FI970246A0 (fi) Dihydrobentsofuraanit
TR200100672T2 (tr) Yeni izoksazolinon antibakteriyel ajanları
DE59708265D1 (de) Neue in 6-position substituierte phenanthridine
DK0937074T3 (da) Benzonaphthyridiner som bronkiale terapeutiske midler
AU5648496A (en) Pyrazolo-(1,5a)pyrimidines, their preparation and their use
SE9502921D0 (sv) New compounds
TR199700206A2 (xx) Floralkil- ve floralkoksi ikame edilmi� heterosiklik bradikinin-antagonistleri, bunlar�n imal edilmesine mahsus usul ve bunlar�n kullan�lmalar�.
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
DE69703796D1 (de) N-bis- oder n-tris-[(1,2-dicarboxy-ethoxy)-ethyl]-amin-derivate und herstellung und anwendung derselben
TR199701202T1 (xx) Yeni hidroksimik asit t�revleri.
NO970341D0 (no) Imidazopyridin-azolidinoner
IT1293777B1 (it) Processo per la preparazione di tetraazamacrocicli
ATE238299T1 (de) N-sulfonylimidazole als fungizide
MX9801133A (es) Agente endoparasiticida a base de didepsipeptidos, nuevos didepsipeptidos y procedimiento para su produccion.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee